Orexo AB (ORX)

Currency in SEK
4.9
-0.2(-3.91%)
Closed·

ORX Earnings

Latest Release
Oct 22, 2026
EPS / Forecast
-2.10 / -2.10
Revenue / Forecast
4.5M / 4.5M
EPS Revisions
Last 90 days
Release Date
Period End
EPS
/Forecast
Revenue
/Forecast
EPS Surprise %
Revenue Surprise %
Reaction
12/2026--/-1.90--/6.00M----Free Sign Up
09/2026-2.10/-2.104.50M/4.50M0%0%Free Sign Up
06/2026-2.20/-1.603.50M/10.10M-37.5%-65.35%Free Sign Up
03/2026-3.00/-0.5705.00M/---426.32%--Free Sign Up
12/2025-3.33/-0.3003.30M/128.90M-1,010%-97.44%Free Sign Up
09/2025-0.860/-0.500118.70M/128.10M-72%-7.34%Free Sign Up
06/2025-1.15/-0.370118.20M/133.20M-210.81%-11.26%Free Sign Up
03/2025-0.460/-0.600146.20M/148.00M+23.33%-1.22%Free Sign Up
12/2024-3.40/-0.970160.30M/154.50M-250.52%+3.75%Free Sign Up
09/2024-1.21/-0.750136.50M/148.10M-61.33%-7.83%Free Sign Up

All numbers in SEK

Orexo AB Earnings Call Summary for Q3/2026

  • Orexo posted Q3 continued operations revenue of SEK 0.8M with net loss of SEK 118M and negative cash flow of SEK 125M amid strategic shift.
  • Shares fell 7.1% to $5, near 52-week low, as company transitions from diversified drugmaker to AmorphOX platform-focused partnership model.
  • Normalized operating expenses at SEK 55M quarterly; management expects further cost reductions in 2027 as restructuring completes and Izipry development ends.
  • Izipry FDA resubmission targets Q1 2025 approval; OX640 pivotal trial starts Q4; rights issue expected to close Q4 2026 for added liquidity.
  • Cash position weakened to SEK 153M from SEK 277M prior quarter; company pursuing partnerships to extend runway beyond 2027 amid minimal revenue base.
Last Updated: 10/22/2026, 08:58 PM
Read Full Transcript

FAQ

What Is Orexo AB's Earnings Per Share (TTM)?

The Orexo AB EPS (TTM) is -12.63.

When Is The Next Orexo AB Earnings Date?

Orexo AB will release its next earnings report on Feb 04, 2027.

What Is Orexo AB’s Revenue Forecasts For Upcoming Quarters?

Orexo AB’s revenue forecast is 6.00M.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.